Oncology - Projects
-
Prospective evaluation of palliative and adjuvant toceranib phosphate therapy in dogs diagnosed with metastatic or recurrent insulinomas
Insulinomas are the most common tumours of the pancreas in dogs. This multi-institutional prospective study evaluates the effectiveness of the drug toceranib phosphate in the treatment of insulinomas in dogs. This is an observational multi-institutional prospective trial. Client preferences regarding control/treatment group allocation will be followed and enrolment will not be blinded or randomised.
-
Identification of novel druggable targets in canine insulinoma through single-cell transcriptomic analysis
Insulinomas in dogs are difficult to cure by surgery. We investigate which genes are crucial for survival of insulinoma cells, allowing us to design new treatments targeted at these genes. Insulinomas are the most common pancreatic neuroendocrine tumours in dogs and humans. Current treatment options are limited to surgery and palliative medical therapy. Survival is poor with a median of 4 [range 0-18] months and 14 [range 0-51] months for medically and surgically treated dogs, respectively. Hence, new, more precise treatments are needed to improve the clinical outcome for dogs and humans with malignant insulinomas.
-
RVC Cancer Biobank
Cancer remains a formidable challenge, affecting both our beloved companion animals and ourselves. The RVC Cancer Biobank takes centre stage as a crucial resource in the quest for biomedical advancements. By offering a standardised approach to biospecimen collection and archiving, our mission is to accelerate cancer research and drive the development of precision medicine. Through the power of linking cancer samples with comprehensive patient information, we can pave the way for more effective, targeted, and less toxic therapies.
-
A Multi-disciplinary Approach to Investigating Canine Diffuse Large B cell Lymphoma
We propose to better define genetic subtypes of canine lymphoma and characterising response to treatment of the different subtypes through a combination of more accurate phenotyping of lymphomas by integrating a) advanced image analysis b) genome sequencing, and c) total RNA sequencing (including micro-RNA sequencing).